Identifying how metabolic changes in mantle cell lymphoma respond to a specific cancer treatment.
Official title: Metabolic Biomarkers of Response of Mantle Cell Lymphoma to Bruton Tyrosine Kinase Inhibition
Funded at University of Pennsylvania · NIH-10792594 · Data updated 2026-11-12
This study is looking at new, gentle ways to see how well treatments for mantle cell lymphoma are working by checking changes in the tumor's metabolism, which could help doctors make quicker decisions about your care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | March 9, 2020 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $477,166 |
| NIH project number | 5R01CA228457-05 |
| Project ID | NIH-10792594 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with mantle cell lymphoma who are undergoing treatment with Bruton Tyrosine Kinase inhibitors.
✕Less likely to help
Patients with other types of cancers or those not receiving Bruton Tyrosine Kinase inhibitors may not benefit from this research.
What this research studies
This research focuses on developing noninvasive methods to detect how mantle cell lymphoma responds to treatment with Bruton Tyrosine Kinase inhibitors. By monitoring metabolic changes in tumors, the study aims to identify early signs of treatment effectiveness or resistance, which can be more reliable than traditional imaging techniques. The approach involves using advanced imaging to track key metabolic pathways affected by the treatment, allowing for timely adjustments in therapy. This could lead to better management of the disease and improved outcomes for patients.
Why it matters
Potential benefit: If successful, this research could enable earlier detection of treatment responses in mantle cell lymphoma, leading to more effective and personalized treatment strategies.
How similar studies have gone: Other research has shown promise in using metabolic monitoring for cancer treatment responses, suggesting that this approach could be effective.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Nath, Kavindra — University of Pennsylvania
- Study coordinator: Nath, Kavindra
Related research
Other NIH-funded projects on the same topics.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Duvelisib for preventing cytokine release syndrome in CAR T-cell therapy patients
A study tests whether taking duvelisib before CAR T-cell therapy can prevent dangerous inflammatory reactions in patients with large B-cell or mantle cell lymphoma.
-
ERBB signaling and ibrutinib resistance in mantle cell lymphoma
A short, patient-friendly look at how scientists study why some mantle cell lymphoma patients stop responding to ibrutinib and how ERBB signaling might be involved.
-
Why some mantle cell lymphomas respond to Notch-blocking drugs
Researchers are looking at DNA regulatory changes to understand why some mantle cell lymphomas respond to drugs that block Notch while others resist them.
-
Preventing a serious side effect of CAR T-cell therapy for lymphoma
This project is testing a new medication called Duvelisib to help prevent a serious immune reaction called cytokine release syndrome in people with large cell or mantle cell lymphoma who are receiving CAR T-cell therapy.
-
Understanding CEACAM1 in Mantle Cell Lymphoma and New Treatments
This research looks for new ways to treat mantle cell lymphoma, especially for patients whose current medications are not working well.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.